BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, December 24, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 21, 1999

View Archived Issues

Cellular immune responses elicited by HGP-30 AIDS vaccine in mice

Read More

AxyS and RPR enter second collaborative agreement

Read More

Pharmacopeia enters research collaboration with Pharmacia & Upjohn

Read More

Italian research team conducts further studies on resveratrol's mechanism of action

Read More

Novartis announces Migranal product introduction in U.K.

Read More

Tyrosine kinase and bone resorption inhibitor isolated from fungus by Takeda

Read More

FDA committee does not recommend approval of Prograf for GVHD

Read More

Nippon Kayaku patents novel squalene synthase inhibitors

Read More

Selective D4 antagonists claimed in patent literature by Shionogi

Read More

D3-selective chromene derivatives synthesized and evaluated at ADIR

Read More

Antimetastatic bis-indoles described in patent literature

Read More

NK1 antagonists in early development at Asahi Glass

Read More

Comtan progressing toward major market launch

Read More

Substance P antagonist prevents emesis in chemotherapy recipients

Read More

Wyeth-Ayerst's nonbenzodiazepine hypnotic zaleplon considered approvable by the FDA

Read More

Chinese herbal medicines prove effective in some IBS patients

Read More

Antex Biologics receives milestone payment from Pasteur Merieux Connaught

Read More

IntraBiotics initiates phase I clinical trial of protegrin IB-367 aerosol

Read More

Adolor receives patent protection for novel approach to analgesia

Read More

Adolor receives additional patent protection for ADL-2-1294

Read More

Meta-analysis supports first-line use of inhaled corticosteroids for allergic rhinitis

Read More

Dopaminergic compound evaluated in small group of PD patients; no evidence of efficacy

Read More

Genome Therapeutics first milestone in alliance with Schering-Plough

Read More

JT reports novel antidiabetic agent that has advanced to clinical trials

Read More

Thyrogen now on the market in U.S.

Read More

Known kappa agonist spiradoline has antiarrhythmic effects in rats

Read More

Ferrer selects new compound for clinical development as atypical antipsychotic

Read More

DuPont presents potent, orally active antiplatelet agent with good duration of action

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 24, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 24, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Acute myeloid leukemia illustration

    Apollo’s APL-4098 shows potent antileukemic effects

    BioWorld Science
    Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
  • Illustration of tau accumulating in a neuron cell.

    ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug

    BioWorld
    ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing